ArticleInternational journal of clinical and experimental medicine2015
Serum osteocalcin levels are inversely associated with the presence of nonalcoholic fatty liver disease in patients with coronary artery disease.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 11 citations in OpenAlex.
- Bone Turnover Markers in Adults with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.International journal of endocrinology · 2023Article
- Crosstalk between bone and other organs.Medical review (2021) · 2022Review
- Low total osteocalcin levels are associated with all-cause and cardiovascular mortality among patients with type 2 diabetes: a real-world study.Cardiovascular diabetology · 2022Article
- Article
- Reduced Serum IGF-1 Associated With Hepatic Osteodystrophy Is a Main Determinant of Low Cortical but Not Trabecular Bone Mass.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2018Article
- Suitable bone markers assessing bone status in patients with both coronary artery disease and diabetes.Journal of diabetes and metabolic disorders · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteocalcin plays roles in energy, glucose, and lipid metabolism. Consequently, the relationship between osteocalcin level and nonalcoholic fatty liver disease (NAFLD) is of interest. The present study explored the possible correlation between serum osteocalcin levels and NAFLD in patients with CAD. The study enrolled 174 inpatients diagnosed with CAD by coronary angiography (CAG). The presence of fatty liver disease was confirmed by abdominal ultrasonography. NAFLD was diagnosed using the working definition of the revised guidelines for the management of NAFLD published by the Chinese Liver Disease Association. Serum osteocalcin levels were determined using electrochemiluminescent immunoassays. Patients with NAFLD had lower serum osteocalcin levels than those without NAFLD [16.2 (14.2-23.8) vs. 20.7 (15.6-26.2) ng/mL, P<0.05]. After adjustment for gender and age, serum osteocalcin levels correlated with the presence of NAFLD (r=-0.260, P=0.010), fasting plasma glucose level (r=-0.230, P=0.023) and glycated hemoglobin A1c level (r=-0.229, P=0.023). Osteocalcin was an independent factor for the presence of NAFLD (β=-0.097, P=0.025). These data suggested that serum osteocalcin levels were negatively associated with the presence of NAFLD in patients with CAD.
Indexed as
Identifiers
26885088PMC4723933W2409815524What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.